Elevation Oncology, Inc. financial metrics

Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q1 2025.

Location
Boston, MA
Fiscal year end
31 December
Latest financial report
15 May 2025

Shareable Research Card

Elevation Oncology, Inc. Financial Facts

Elevation Oncology, Inc. has a source-backed company facts page for reviewing reported financial metrics, periods, and linked metric histories.

Start with the latest metric summary, then open metric histories or cross-company rankings to compare the same SEC-backed facts.

Context
Latest metrics period: Q1 2025
Latest reported value
Return On Equity -78%

Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.

Open stable link Open latest 10-Q/10-K hub Which companies report the highest net income?

Return Loop

Why revisit this company facts page

Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.

Latest source-backed update
Latest metrics period Q1 2025
Why come back
Use the next filing cycle to compare new facts against this baseline and then verify the detailed metric history.
  • Current latest metrics period: Q1 2025.
  • Most recent SEC facts end date on this page: 31 Mar 2025.
  • Save this filer to return when the next filing-backed metric period changes the picture.

Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.

Create account to save this filer Open latest 10-Q/10-K hub

Latest update

Latest update for Elevation Oncology, Inc.

New fact period available

Latest financial period: Q1 2025. Reopen this facts page to verify the newest reported period against the prior baseline.

Update date

15 May 2025

Page type

Company facts

Latest period

Q1 2025

SEC-backed company facts were refreshed from filings filed on 15 May 2025.

Open recent updates hub Open latest 10-Q/10-K hub

Benchmark Context

How Return On Equity compares

Return On Equity is up about 9% versus the comparable prior period.

Compared with

Compared with Elevation Oncology, Inc.'s recent history first. Same-industry peer context appears only when enough SEC-backed benchmark coverage exists.

Why this is notable

Return On Equity already has a self-history signal here, but same-industry benchmark context waits until the benchmark sample is strong enough.

  • Latest comparable period on this page: Q1 2025.
  • Peer context will appear when enough companies report a comparable value for this metric.
  • Open the metric history first if you want to verify the exact period-to-period change.

Industry benchmark context uses SEC-reported values from the same methodology version. Latest periods may differ across companies.

Open NetIncomeLoss YoY history Which companies report the highest net income?

How to read key metrics on this page

These short guides explain what the headline metrics mean, what to compare next, and where to open the live SEC-backed example for this company.

Plain-English Guide

How to read Net Income on this page

Net income is profit after operating costs, interest, taxes, and other non-operating items.

Why people care

It is the bottom-line profit figure many users recognize first, especially when they want to compare earnings with sales or cash flow.

How to read it

Use the same quarter or fiscal year comparison first, then check operating income or cash flow if the bottom line moved sharply.

Compare next

Compare it with operating income, EPS, and operating cash flow to see whether earnings are broad-based or driven by one-off items.

Net income can swing because of tax, financing, or accounting adjustments, so it is often less comparable than core operating metrics.

Open a live SEC-backed example

Open Net Income guide

Save this filer page

Create a free account to keep this page in your watchlists and return after a new SEC filing changes the record here.

Create free account to save and revisit this page

Quick Takeaways

  • Elevation Oncology, Inc. financial facts are built from SEC company filings data.
  • Latest metrics period on this page: Q1 2025.
  • Headline metric: Return On Equity -78%.

What Changed

  • Return On Equity YoY change: +9%.
  • Most recent SEC facts end date: 31 Mar 2025.

Why This Matters

  • This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
  • Every metric card links to a deeper SEC-backed history page for verification.

Source Evidence

Based on latest 10-Q/10-K

Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.

See Original Filing

Latest SEC snapshot (2025-03-31) highlights Return On Equity -78.3%, Return On Assets -50.2%, and Current Ratio 19.4x.

Compare This Company Through SEC-backed Metrics

Use these links to compare Elevation Oncology, Inc. against other SEC filers on the same metric, then verify the company history from the paired facts page.

Financial Quality Score

Transparent 0-100 scoring model based on profitability, financial health, and growth factors.

17.1/100

Weak Confidence medium

Return On Equity

-78%

Metric score 0.0/100

Return On Assets

-50%

Metric score 0.0/100

Financial Health

Current Ratio
19.4x
Debt to Equity
0.55x

Strengths

Debt-to-equity

Watchpoints

Return On Equity, Return On Assets, and Current Ratio

Key metrics snapshot

Profitability

Metric Latest value YoY change
Return On Equity -78% +9%
Return On Assets -50% +19%

Financial Health

Metric Latest value YoY change
Current Ratio 19.4x -58%
Debt-to-equity 0.55x +2.1%

Growth

Metric Latest value YoY change
NetIncomeLoss YoY -22%

Share Metrics

Metric Latest value YoY change
Entity Common Stock, Shares Outstanding 59,215,795 +8.4%
Common Stock, Shares, Outstanding 59,223,729 +15%
Common Stock, Value, Issued $6,000 +20%
Weighted Average Number of Shares Outstanding, Basic 59,173,854 +14%
Weighted Average Number of Shares Outstanding, Diluted 59,173,854 +14%

Supporting Metrics

These supporting metrics stay fully source-backed for deeper research. Scan the latest value and reported period first, then open a metric page when you need the full filing trail.

Metric Latest value YoY change
Accounts Payable, Current $492,000 +13%
Accrued Liabilities, Current $3,744,000 +97%
Accumulated Other Comprehensive Income (Loss), Net of Tax $11,000
Additional Paid in Capital $301,507,000 +6.7%
Assets $82,223,000 -25%
Assets, Current $82,194,000 -24%
Cash and Cash Equivalents, at Carrying Value $60,494,000 -33%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $60,494,000 -33%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $11,030,000 -73%
Common Stock, Par or Stated Value Per Share 0 0%
Common Stock, Shares Authorized 500,000,000 0%
Common Stock, Shares, Issued 59,316,859 +15%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $47,978,000 -22%
Depreciation $5,000 -50%
Earnings Per Share, Basic -1 -9.5%
Earnings Per Share, Diluted -1 -9.5%
General and Administrative Expense $16,213,000 +12%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $47,951,000 -22%
Income Tax Expense (Benefit) $38,000 +5.6%
Interest Paid, Excluding Capitalized Interest, Operating Activities $806,000 -9.1%
Liabilities $35,489,000 +7.1%
Liabilities and Equity $82,223,000 -25%
Liabilities, Current $4,236,000 +81%
Marketable Securities, Current $20,165,000 +50%
Net Cash Provided by (Used in) Investing Activities $23,758,000 +15%
Net Cash Provided by (Used in) Operating Activities $12,711,000 -33%
Operating Income (Loss) $49,050,000 -27%
Other Assets, Noncurrent $0 -100%
Preferred Stock, Par or Stated Value Per Share 0 0%
Preferred Stock, Shares Authorized 10,000,000 0%
Preferred Stock, Shares Issued 0
Preferred Stock, Shares Outstanding 0
Property, Plant and Equipment, Net $29,000 -41%
Research and Development Expense $29,462,000 +22%
Retained Earnings (Accumulated Deficit) $254,666,000 -23%
Share-based Payment Arrangement, Expense $4,365,000 +57%
Share-based Payment Arrangement, Noncash Expense $987,000 +9.4%
Stockholders' Equity Attributable to Parent $46,734,000 -38%

How we score

This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.

Metric Weight V1 threshold
ROIC205% to 20%
ROE158% to 25%
ROA102% to 10%
Operating Margin55% to 25%
Current Ratio121.0x to 2.0x
Quick Ratio80.8x to 1.5x
Debt to Equity100.3x to 2.0x (lower is better)
Revenue YoY10-10% to +20%
Net Income YoY10-10% to +20%

How Calculated (standard_v1)

Metrics are computed with a market-consensus convention designed for cross-portal comparability.

  • TTM Operating Income / TTM Revenues
  • Current Assets / Current Liabilities (latest instant quarter)
  • (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
  • Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
  • TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
  • TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
  • TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
  • TTM Revenues YoY
  • TTM Net Income YoY
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .